Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists

J Nucl Med. 2018 Mar;59(3):546-547. doi: 10.2967/jnumed.117.202630. Epub 2017 Oct 6.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Indium Radioisotopes
  • Octreotide / analogs & derivatives
  • Organometallic Compounds
  • Receptors, Somatostatin*
  • Somatostatin*
  • Tissue Distribution
  • Yttrium Radioisotopes

Substances

  • Indium Radioisotopes
  • Organometallic Compounds
  • Receptors, Somatostatin
  • Yttrium Radioisotopes
  • Yttrium-90
  • Somatostatin
  • lutetium Lu 177 dotatate
  • Indium-111
  • Octreotide